CLINICAL STUDY OF LONG-TERM ROXITHROMYCIN (RXM) THERAPY AFTER ENDOSCOPIC SINUS SURGERY

• Published in: JIBI INKOKA TEMBO Vol. 40; no. Supplement2; pp. 114 - 120
• Main Authors: Saiki, Tadahiko, Joko, Hideo, Aritomo, Hiroshi, Nakamura, Koshiro, Aibara, Ryuichi
• Format: Journal Article
• Language: Japanese
• Published: Society of Oto-rhino-laryngology Tokyo 1997
• Subjects: chronic paranasal sinusitis; endoscopic sinus surgery; roxithromycin
• ISSN: 0386-9687; 1883-6429
• DOI: 10.11453/orltokyo1958.40.Supplement2_114

The clinical efficacy of a long-term RXM therapy after endoscopic sinus surgery in patients with chronic paranasal sinusitis was investigated in comparison with the therapy without RXM after surgery. In twenty three patients, RXM was orally administrated 300 mg per day for an average of 15.7 weeks after surgery. Thirteen patients were treated without administration of RXM after surgery. Improve-ment rate of subjective symptoms was 65.2% in the group with RXM and 53.8% in the group without RXM, respectively. Objective findings were found to be improved in 92.5% and 60.0% of patients in each group. The overall improvement rate based on the changes in subjective and objective findings was 63.6% and 44.4%, respectively. Postoperative CT findings showed marked improvement in 81.8% of the group with RXM and in 58.8% of the group without RXM. Under endoscopic examination, mucosal pathology of the group with RXM was better than that of the group without RXM in anterior and posterior ethomoid sinuses. Openings of the middle nasal meatus and fontanelle were 88.6% and 95.5% in the group with RXM, and 90.0% and 95.0% in the group without RXM, respectively. These results suggest that long-term RXM therapy after endoscopic sinus surgery is more effective than the therapy without RXM after surgery in the patients with chronic paranasal sinusitis.